Oncology Institute Statistics
Share Statistics
Oncology Institute has 89.19M
shares outstanding. The number of shares has increased by 1.77%
in one year.
| Shares Outstanding | 89.19M |
| Shares Change (YoY) | 1.77% |
| Shares Change (QoQ) | 0.26% |
| Owned by Institutions (%) | 19.48% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 5,619 |
| FTD / Avg. Volume | 0.47% |
Short Selling Information
The latest short interest is 1.48M, so 1.69% of the outstanding
shares have been sold short.
| Short Interest | 1.48M |
| Short % of Shares Out | 1.69% |
| Short % of Float | 2.09% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.36 and the forward
PE ratio is -30.
Oncology Institute's PEG ratio is
0.
| PE Ratio | -0.36 |
| Forward PE | -30 |
| PS Ratio | 0.06 |
| Forward PS | 0.4 |
| PB Ratio | 6.46 |
| P/FCF Ratio | -0.76 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Oncology Institute.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.15,
with a Debt / Equity ratio of 34.31.
| Current Ratio | 2.15 |
| Quick Ratio | 1.96 |
| Debt / Equity | 34.31 |
| Debt / EBITDA | -2.42 |
| Debt / FCF | -4.06 |
| Interest Coverage | -8.02 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $476,863.03 |
| Profits Per Employee | $-78,379.39 |
| Employee Count | 825 |
| Asset Turnover | 2.28 |
| Inventory Turnover | 33.81 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 449.09% in the
last 52 weeks. The beta is 0.07, so Oncology Institute's
price volatility has been higher than the market average.
| Beta | 0.07 |
| 52-Week Price Change | 449.09% |
| 50-Day Moving Average | 2.02 |
| 200-Day Moving Average | 0.83 |
| Relative Strength Index (RSI) | 58.65 |
| Average Volume (20 Days) | 1,202,683 |
Income Statement
In the last 12 months, Oncology Institute had revenue of 393.41M
and earned -64.66M
in profits. Earnings per share was 0.
| Revenue | 393.41M |
| Gross Profit | 54M |
| Operating Income | -60.12M |
| Net Income | -64.66M |
| EBITDA | -50.88M |
| EBIT | -57.17M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 49.67M in cash and 123.15M in
debt, giving a net cash position of -73.48M.
| Cash & Cash Equivalents | 49.67M |
| Total Debt | 123.15M |
| Net Cash | -73.48M |
| Retained Earnings | -210.81M |
| Total Assets | 164M |
| Working Capital | 47.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -26.54M
and capital expenditures -3.79M, giving a free cash flow of -30.33M.
| Operating Cash Flow | -26.54M |
| Capital Expenditures | -3.79M |
| Free Cash Flow | -30.33M |
| FCF Per Share | -0.4 |
Full Cash Flow StatementMargins
Gross margin is 13.73%, with operating and profit margins of -15.28% and -16.44%.
| Gross Margin | 13.73% |
| Operating Margin | -15.28% |
| Pretax Margin | -16.44% |
| Profit Margin | -16.44% |
| EBITDA Margin | -12.93% |
| EBIT Margin | -15.28% |
| FCF Margin | -7.71% |
